Lingering visual changes in psychedelic users: a Yale study of 186 people

Related Articles

Psiconáutica Editorial Team · November 16, 2026

In brief

  • A Yale University team studied 186 people who use serotonergic psychedelics, recruited largely through online forums, using questionnaires and a laboratory visual task.
  • According to Yale’s article, more than half reported persisting visual abnormalities that, by their own account, began after use. In addition, over 90% of all participants reported no distress.
  • It is a cross-sectional study with a self-selected sample: it does not show that psychedelics cause these abnormalities, nor does it measure psychosis risk.
Read more  FDA psychedelic hearing: scope of the July notice

Some people notice changes in what they see long after taking LSD, psilocybin or other psychedelics, such as brighter colours. The clinical form, hallucinogen persisting perception disorder (HPPD), requires clinically meaningful distress or impairment and is not commonly diagnosed. A paper in Scientific Reports drops that requirement to study the phenomenon more broadly and compares it with a test used in psychosis research.

What was studied

The paper is by Maximillian S. Greenwald, Albert R. Powers and six co-authors from Yale, the University of Zurich and ETH Zurich, Aarhus University and the University of Pennsylvania. It was published on 28 September 2026 as an accepted manuscript, a version the journal warns may change before the final Version of Record. Yale School of Medicine publicised it on 3 November.

Participants reported their psychedelic use and their persisting perceptual abnormalities, past and current. They then completed a ‘conditioned hallucinations’ task: a tone is first paired with faint stripes hidden in visual static, and the tone is later played without stripes to see whether the person still reports seeing them. The team fitted a computational model to those responses.

What they found

According to the abstract, both past and current abnormalities were associated with starting use at a younger age, higher doses, lower visual thresholds, more conditioned hallucinations (and greater confidence in them) and a reduced ability to tell real stimuli from noise. Of the model parameters, only reduced ‘decision precision’ tracked both measures and statistically mediated the relationship between dose and abnormalities. The abstract describes the rise in the weight given to expectations as equivocal; Yale’s article summarises this by saying these participants did not rely more heavily on expectations.

Read more  Ibogaine: federal research support and unresolved cardiac risk

The authors suggest these abnormalities may reflect a ‘noisy’ visual system that is prone to detecting something even when nothing is there. This is an interpretation, not a demonstrated mechanism.

What Yale’s article adds

The article provides proportions that are not in the abstract. More than half of the sample reported abnormalities that began after use, and the most common change was seeing brighter colours. In addition, ‘more than 90% of participants’ reported no distress. Yale gives this figure for the participants as a whole and does not say what share of those with abnormalities felt distress. Powers notes that unusual sensory experiences often appear before a first psychotic episode, on average about 22 months earlier. Greenwald cautions that when someone develops psychosis after using psychedelics, it is hard to know whether they would have developed it anyway.

Limitations

  • The design is cross-sectional with volunteers recruited online: it does not represent all users and does not allow causal attribution, as the university itself acknowledges.
  • Use, doses and abnormalities rely on participants’ own reports, partly retrospective.
  • The high proportion depends on a broad definition without a distress requirement; it is not the frequency of clinical HPPD.
  • Statistical mediation in cross-sectional data does not prove a mechanism.
  • The study does not measure psychosis risk.
  • We have only read the article’s abstract and Yale’s news article. We could not review the full methods, effect sizes, any correction for multiple comparisons or the supplementary material, so we do not assess those aspects.
Read more  Psilocybin and phantom-limb pain: a nine-person pilot

What it means

From a harm-reduction perspective, the finding suggests that, in a broad sense, lasting visual changes may be more common than the clinical diagnosis implies. Even so, the great majority of participants in this self-selected sample reported no distress. According to Yale, the association with starting use at a younger age is consistent with earlier research in which adolescent users reported these abnormalities more often than adults. None of this shows that one causes the other. If a perceptual change causes anxiety, interferes with daily life or gets worse, it makes sense to discuss it with a healthcare professional. More context in our guide to harm reduction and responsible drug use and in our report on self-attributed health outcomes of MDMA and other psychedelics in a survey.

Sources

Image

Illustrative image: the Anlyan Center, a Yale School of Medicine building in New Haven, Connecticut, at the corner of Cedar Street, photographed on 29 October 2024. It does not document the study or its participants. Photo: Ajay Suresh, via Wikimedia Commons (original on Flickr), licensed under CC BY 2.0.

Educational content produced from a harm-reduction perspective and with respect for individual freedom. It does not replace information from a healthcare professional and is not intended to encourage or condemn any drug use.

More on this topic

Comments

Advertisementspot_img

Popular stories